Sirolimus as primary immunosuppression is effective in attenuating progression of cardiac-allograft vasculopathy
Joren C Madsen
Correspondence Massachusetts General Hospital, Department of Surgery, Cox 654, 55 Fruit Street, Boston, MA 02114, USA
Email madsen@helix.mgh.harvard.edu
This article has no abstract so we have provided the first paragraph of the full text.
Heart transplantation has become a victim of its own success. Patients are surviving long enough to develop complications caused by the powerful immunosuppressive agents administered after transplantation. These complications include cancer from chronic, nonspecific immunosuppression; renal failure caused by CNI, such as ciclosporin and tacrolimus, and CAV. The latter is a manifestation of chronic allograft rejection and is a major cause of late graft failure. The incidence and impact of these long-term complications account for the disappointing less than 60% 10-year survival rate of heart transplant recipients1 A new approach to long-term immunosuppression therapy is needed.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
